Viewing Study NCT03297606


Ignite Creation Date: 2025-12-26 @ 5:23 PM
Ignite Modification Date: 2025-12-31 @ 6:02 PM
Study NCT ID: NCT03297606
Status: RECRUITING
Last Update Posted: 2025-09-16
First Post: 2017-09-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Sponsor: Canadian Cancer Trials Group
Organization:

Study Overview

Official Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Status: RECRUITING
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CAPTUR
Brief Summary: Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Detailed Description: Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumors that might be responsible for their malignant behavior such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centers and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumors to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumor profiling and have 'druggable' changes identified in their cancers.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
ESR-17-12831 OTHER AstraZeneca View
CA209-9DL OTHER Bristol-Myers Squibb View
ML39800 OTHER Hoffmann-La Roche View
WI233446 OTHER Pfizer View